Assessing the role of venetoclax in combination with hypomethylating agents in higher risk myelodysplastic syndrome

• Rami S. Komrokji,
• Avani M. Singh,
• Najla Al Ali,
• Onyee Chan,
• Eric Padron,
• Kendra Sweet,
• Andrew Kuykendall,
• Jeffrey E. Lancet,
• David A. Sallman

Affiliations

Rami S. Komrokji

Department of Malignant Hematology, H. Lee Moffitt Cancer Center & Research Institute

Avani M. Singh

Department of Hematology/Oncology, University of South Florida & Moffitt Cancer Center

Najla Al Ali

Department of Malignant Hematology, H. Lee Moffitt Cancer Center & Research Institute

Onyee Chan

Department of Malignant Hematology, H. Lee Moffitt Cancer Center & Research Institute

Eric Padron

Department of Malignant Hematology, H. Lee Moffitt Cancer Center & Research Institute

Kendra Sweet

Department of Malignant Hematology, H. Lee Moffitt Cancer Center & Research Institute

Andrew Kuykendall

Department of Malignant Hematology, H. Lee Moffitt Cancer Center & Research Institute

Jeffrey E. Lancet

Department of Malignant Hematology, H. Lee Moffitt Cancer Center & Research Institute

David A. Sallman

Department of Malignant Hematology, H. Lee Moffitt Cancer Center & Research Institute